hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
=== Hoechst stains === Hoechst is a bis-benzimidazole derivative compound that binds to the minor groove of DNA. Often used in fluorescence microscopy for DNA staining, Hoechst stains appear yellow when dissolved in aqueous solutions and emit blue light under UV excitation. There are two major types of Hoechst: Hoechst 33258 and Hoechst 33342. The two compounds are functionally similar, but with a little difference in structure. Hoechst 33258 contains a terminal hydroxyl group and is thus more soluble in aqueous solution, however this characteristics reduces its ability to penetrate the plasma membrane. Hoechst 33342 contains an ethyl substitution on the terminal hydroxyl group (i.e. an ethylether group) making it more hydrophobic for easier plasma membrane passage
However, the direct calorimetric method generally overestimates the actual energy that the body can obtain from the food, because it also counts the energy contents of dietary fiber and other indigestible components, and does not allow for partial absorption and/or incomplete metabolism of certain substances. For this reason, today the energy content of food is instead obtained indirectly, by using chemical analysis to determine the amount of each digestible dietary component (such as protein, carbohydrates, and fats), and adding the respective food energy contents, previously obtained by measurement of metabolic heat released by the body. In particular, the fibre content is excluded. This method is known as the Modified Atwater system, after Wilbur Atwater who pioneered these measurements in the late 19th century. The system was later improved by Annabel Merrill and Bernice Watt of the USDA, who derived a system whereby specific calorie conversion factors for different foods were proposed.
== Career == In the early 1920s, Harald Pedersen worked with Nobel laureate August Krogh (and others) at the Laboratory of Zoophysiology; his mechanical workshop produced machines used in early insulin production. In autumn 1923, his brother Thorvald was hired by Nordisk Insulinlaboratorium to analyse chemical processes in insulin production; Harald also worked at Nordisk.
In this role, she serves as an advocate and liaison for basic science researchers working in clinical departments to help facilitate the combination of “basic research” which seeks to answer fundamental scientific questions and “translational research” that seeks to put those findings to use, for example in a clinical setting. In 2020, she was named director of the department of pharmacology and molecular sciences at Johns Hopkins University School of Medicine, becoming the first African-American director of a basic science department, and the first Black woman to chair any department, at Johns Hopkins University School of Medicine. Outside of Johns Hopkins, Bumpus chaired the National Institute of Health (NIH)'s Xenobiotic and Nutrient Disposition and Action study section and served as a science commissioner and member of Washington, D.C.’s Science Advisory Board. She was an associate editor of the journal Drug Metabolism and Disposition. She has been strongly involved with the American Society for Pharmacology and Experimental Therapeutics (ASPET), where she served as secretary and treasurer and president.
Sources: en.wikipedia.org
For example, it was shown that the reaction of oganesson with F2 to form the compound OgF2 would release an energy of 106 kcal/mol of which about 46 kcal/mol come from these interactions. For comparison, the spin–orbit interaction for the similar molecule RnF2 is about 10 kcal/mol out of a formation energy of 49 kcal/mol. The same interaction stabilizes the tetrahedral Td configuration for OgF4, as distinct from the square planar D4h one of XeF4, which RnF4 is also expected to have; this is because OgF4 is expected to have two inert electron pairs (7s and 7p1/2). As such, OgF6 is expected to be unbound, continuing an expected trend in the destabilisation of the +6 oxidation state (RnF6 is likewise expected to be much less stable than XeF6). The Og–F bond will most probably be ionic rather than covalent, rendering the oganesson fluorides non-volatile. OgF2 is predicted to be partially ionic due to oganesson's high electropositivity. Oganesson is predicted to be sufficiently electropositive to form an Og–Cl bond with chlorine. A compound of oganesson and tennessine, OgTs4, has been predicted to be potentially stable chemically.
== Effects upon US public opinion == One effect of the dispute in the US was to awaken the public's interest in the issue. This interest was not wholly unsympathetic to the EU. In 1989, for example, the Consumer Federation of America and the Center for Science in the Public Interest both pressed for an adoption of a ban within the US similar to that within the EU. In a study done in 2002, 85% of respondents wanted mandatory labeling on beef produced with growth hormones.
Hans Studener (1966–1969) Kurt Holke (1969–1971) Horst Scherbaum (1971–1976) Manfred Pfeifer (1976–1978) Heinz Joerk (1978–1979) Harro Miller (1979–1985) Hans-Ulrich "Uli" Thomale (1985 – February 1990) Gunter Böhme (February 1990 – 27 May 1991) VfB Leipzig
Sources: en.wikipedia.org
Some forms of MODY produce significant hyperglycemia and the typical signs and symptoms of diabetes: increased thirst and urination (polydipsia and polyuria). In contrast, many people with MODY have no signs or symptoms and are diagnosed either by accident, when a high glucose is discovered during testing for other reasons, or screening of relatives of a person discovered to have diabetes. Discovery of mild hyperglycemia during a routine glucose tolerance test for pregnancy is particularly characteristic. While the goals of diabetes management are the same no matter what type, there are two primary advantages of confirming a diagnosis of MODY.
=== T cell epitopes === T cell epitopes are presented on the surface of an antigen-presenting cell, where they are bound to major histocompatibility complex (MHC) molecules. In humans, professional antigen-presenting cells are specialized to present MHC class II peptides, whereas most nucleated somatic cells present MHC class I peptides. T cell epitopes presented by MHC class I molecules are typically peptides between 8 and 11 amino acids in length, whereas MHC class II molecules present longer peptides, 13–17 amino acids in length, and non-classical MHC molecules also present non-peptidic epitopes such as glycolipids.
== History == Medtronic replaced the Paradigm insulin pump with its new pump platform, the 640G, internationally in 2015. Its successive pumps have used the same form factor. In the United States, the 670G was released in 2017. It used an algorithm called SmartGuard to adjust the basal insulin rate based on readings from the CGM (continuous glucose monitor). A more advanced SmartGuard algorithm was released in 2020 (2023 in the United States) as part of the 780G. It can deliver automated boluses and has an optional glucose target of 100 mg/dl. The 670G used Medtronic's own proprietary algorithm. For the 780G, the SmartGuard algorithm was adapted from an algorithm licensed by Medtronic in 2015 from medical technology company DreaMed. DreaMed, based at the Schneider Children's Medical Center of Israel in Tel Aviv, created the algorithm in the late 2000s. At first called MD-Logic Artificial Pancreas, then GlucoSitter, it used machine learning to increase the patient's time in the 80–120 mg/dl range. DreaMed's algorithm performed well in clinical trials as of 2011. Initially, the pump was compatible only with MiniMed's own CGMs, the Guardian 3 and Guardian 4. In 2025, MiniMed introduced two new CGMs for the 780G, the Simplera Sync and the Instinct, made by Abbott Laboratories.
The three substrates of this enzyme are 4-guanidinobutanal, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are 4-guanidinobutyric acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 4-guanidinobutanal:NAD+ 1-oxidoreductase. Other names in common use include alpha-guanidinobutyraldehyde dehydrogenase, 4-guanidinobutyraldehyde dehydrogenase, and GBAL dehydrogenase. This enzyme participates in urea cycle and metabolism of amino groups.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.